Amplia Therapeutics Limited (ASX:ATX)

Market Cap	61.60M -27.2%
Revenue (ttm)	4.79M +26.6%
Net Income	-7.71M
EPS	-0.02
Shares Out	513.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	109,243
Open	0.1220
Previous Close	0.1200
Day's Range	0.1220 - 0.1250
52-Week Range	0.1000 - 0.2750
Beta	-0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 10, 2026

About Amplia Therapeutics

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limite...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ATX

Financial Performance

In fiscal year 2026, Amplia Therapeutics's revenue was 4.79 million, an increase of 26.63% compared to the previous year's 3.78 million. Losses were -7.71 million, 17.3% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error